Show simple item record

dc.contributor.authorWenzler, Tanja
dc.contributor.authorYang, Sihyung
dc.contributor.authorPatrick, Donald A.
dc.contributor.authorBraissant, Olivier
dc.contributor.authorIsmail, Mohamed A.
dc.contributor.authorTidwell, Richard R.
dc.contributor.authorBoykin, David W.
dc.contributor.authorWang, Zhuo
dc.contributor.authorBrun, Reto
dc.identifier.citationWenzler, T., S. Yang, D. A. Patrick, O. Braissant, M. A. Ismail, R. R. Tidwell, D. W. Boykin, M. Z. Wang, and R. Brun. "In Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sickness." Antimicrobial Agents and Chemotherapy 58.8 (2014): 4452-463.
dc.descriptionThis is the published version.en_US
dc.description.abstractAfrican sleeping sickness is a neglected tropical disease transmitted by tsetse flies. New and better drugs are still needed especially for its second stage, which is fatal if untreated. 28DAP010, a dipyridylbenzene analogue of DB829, is the second simple diamidine found to cure mice with central nervous system infections by a parenteral route of administration. 28DAP010 showed efficacy similar to that of DB829 in dose-response studies in mouse models of first- and second-stage African sleeping sickness. The in vitro time to kill, determined by microcalorimetry, and the parasite clearance time in mice were shorter for 28DAP010 than for DB829. No cross-resistance was observed between 28DAP010 and pentamidine on the tested Trypanosoma brucei gambiense isolates from melarsoprol-refractory patients. 28DAP010 is the second promising preclinical candidate among the diamidines for the treatment of second-stage African sleeping sickness.en_US
dc.publisherAmerican Society for Microbiologyen_US
dc.titleIn Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sicknessen_US
kusw.kuauthorWang, Zhuo
kusw.kudepartmentPharmaceutical Chemistryen_US
kusw.oanotesPer SHERPA/RoMEO, 12/31/15: Author's Pre-print: green tick author can archive pre-print (ie pre-refereeing) Author's Post-print: green tick author can archive post-print (ie final draft post-refereeing) Publisher's Version/PDF: green tick author can archive publisher's version/PDF General Conditions:

Author's pre-print on recognised non profit pre-print archives Author's post-print on funder's repositories, institutional repository or subject-based repositories Non-commercial Publisher's version/PDF may be used Publisher's version/PDF may be used on author's personal website or employers website Recommended that author's post-prints submitted to PubMed or institutional repositories are made available 6 months after publication Author's pre-print must be updated with citation and DOI upon publication
kusw.oaversionScholarly/refereed, publisher version
kusw.oapolicyThis item meets KU Open Access policy criteria.

Files in this item


This item appears in the following Collection(s)

Show simple item record